Abivax Aktie 28479075 / FR0012333284
7.08
EUR
0.00
EUR
0.00%
24.12.2024
PAR
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Abivax SA Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Abivax SA | 0.00 | 0.00 | EUR |
| 2022 | Abivax SA | 0.00 | 0.00 | EUR |
| 2021 | Abivax SA | 0.00 | 0.00 | EUR |
| 2020 | Abivax SA | 0.00 | 0.00 | EUR |
| 2019 | Abivax SA | 0.00 | 0.00 | EUR |
| 2018 | Abivax SA | 0.00 | 0.00 | EUR |
| 2017 | Abivax SA | 0.00 | 0.00 | EUR |
| 2016 | Abivax SA | 0.00 | 0.00 | EUR |
| 2015 | Abivax SA | 0.00 | 0.00 | EUR |
| 2014 | Abivax SA | - | - | EUR |
Zu diesem Datensatz liegen uns leider keine Daten vor.
Abivax SA Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Abivax SA | Quartalszahlen | 13.03.2025 |
| Abivax SA | Quartalszahlen | 26.09.2025 |
Abivax SA vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 07.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 09.09.2024 |
| Hauptversammlung | Annual General Meeting | 30.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 02.04.2024 |
| Quartalszahlen | Q2 2023 Earnings Release | 21.09.2023 |
| Hauptversammlung | Annual General Meeting | 05.06.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 19.04.2023 |
| Quartalszahlen | Q2 2022 Earnings Release | 15.09.2022 |
| Hauptversammlung | Annual General Meeting | 09.06.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 16.03.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 62.51 |
| Invus Financial Advisors LLC | 10.32 |
| TCG Crossover Management LLC | 9.44 |
| Sofinnova Partners SAS | 8.31 |
| Truffle Capital SAS | 7.68 |
| Deep Track Capital LP | 4.93 |
| VHCP Management LLC | 4.12 |
| DNCA Invest - Beyond Global Leaders | 1.18 |
| Paolo Rampulla | 1.17 |
| HBM Healthcare Investments AG | 1.11 |
| Pictet - Biotech | 0.86 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 26 | 27 | 26 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Bilanz (in Mio. EUR) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 21 | 21 | 17 | 37 | 75 |
| Summe Anlagevermögen | 33 | 33 | 35 | 35 | 36 |
| Summe Aktiva | 54 | 54 | 52 | 71 | 110 |
Bilanz (in Mio. EUR) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 10 | 25 | 40 | 67 | 82 |
| Summe Eigenkapital | 44 | 29 | 12 | 5 | 29 |
| Summe Passiva | 54 | 54 | 52 | 71 | 110 |
Adresse
| 7-11 Boulevard Haussmann, 75009 Paris | |
| Telefon | +33 (1) 53-83-09-63 |
| URL | http://www.abivax.com |
Management
|
Camilla Soenderby
Director |
|
Christopher Rabbat
Head-Medical Affairs & Vice President |
|
Corinna Zur Bonsen-Thomas
Independent Director |
|
David Zhang
Chief Strategy Officer |
|
Didier Blondel
Chief Financial Officer, Secretary & EVP |
|
Didier Scherrer
Chief Scientific Officer |
|
Fabio Cataldi
Chief Medical Officer |
|
Hema Keshava
Senior Vice President-Finance |
|
Ida Hatoum
Chief People & Compliance Officer |
|
June H Lee
Director |
|
Kinam Hong
Director |
|
Marc M. P. de Garidel
Chief Executive Officer |
|
Patrick Malloy
Senior Vice President-Investor Relations |
|
Pierre Courteille
Chief Business Officer |
|
Sharon Skare
Head-Clinical Operations & Vice President |
|
Sylvie Louise Grégoire
Chairman |
|
Troy A. Ignelzi
Director |